Pharmaceutical Technology6 小时
Cabometyx by Exelixis for Salivary Gland Cancer: Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...
Pharmaceutical Technology6 小时
Ninsipapogene sibarnarepvec by Hookipa Pharma for Recurrent Head And Neck Squamous Cell ...
Ninsipapogene sibarnarepvec is under clinical development by Hookipa Pharma and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.